Mustang Bio Stock Revenue
| MBIO Stock | USD 0.20 0.01 5.26% |
Mustang Bio fundamentals help investors to digest information that contributes to Mustang Bio's financial success or failures. It also enables traders to predict the movement of Mustang Stock. The fundamental analysis module provides a way to measure Mustang Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mustang Bio stock.
| Last Reported | Projected for Next Year |
Mustang | Revenue |
Mustang Bio Company Revenue Analysis
Mustang Bio's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Mustang
Projected quarterly revenue analysis of Mustang Bio provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Mustang Bio match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Mustang Bio's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Mustang Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Mustang Bio reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Mustang Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mustang Bio's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mustang Bio could also be used in its relative valuation, which is a method of valuing Mustang Bio by comparing valuation metrics of similar companies.Mustang Bio is currently under evaluation in revenue category among its peers.
Mustang Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Mustang Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mustang Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mustang Bio's value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 17.9 K | Northern Trust Corp | 2024-09-30 | 16.9 K | State Street Corp | 2024-06-30 | 16 K | Jamison Private Wealth Management Inc | 2024-09-30 | 15 K | Jump Financial Llc | 2024-09-30 | 10.8 K | Fmr Inc | 2024-09-30 | 10.2 K | Macquarie Group Ltd | 2024-06-30 | 8 K | Harbour Investments, Inc. | 2024-09-30 | 3.8 K | Wells Fargo & Co | 2024-06-30 | 3 K | Geode Capital Management, Llc | 2024-09-30 | 245.5 K | Ubs Group Ag | 2024-06-30 | 193.6 K |
Mustang Fundamentals
| Return On Equity | -11.91 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 6.54 M | ||||
| Shares Outstanding | 46.93 M | ||||
| Shares Owned By Insiders | 5.86 % | ||||
| Shares Owned By Institutions | 5.94 % | ||||
| Number Of Shares Shorted | 424.91 K | ||||
| Price To Earning | (11.40) X | ||||
| Price To Book | 31.75 X | ||||
| EBITDA | (48.06 M) | ||||
| Net Income | (51.6 M) | ||||
| Cash And Equivalents | 107.37 M | ||||
| Cash Per Share | 1.01 X | ||||
| Total Debt | 2.5 M | ||||
| Debt To Equity | 0.35 % | ||||
| Current Ratio | 9.96 X | ||||
| Book Value Per Share | (0.94) X | ||||
| Cash Flow From Operations | (49.48 M) | ||||
| Short Ratio | 0.10 X | ||||
| Earnings Per Share | (1.33) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 80 | ||||
| Beta | 1.92 | ||||
| Market Capitalization | 9.53 M | ||||
| Total Asset | 17.74 M | ||||
| Retained Earnings | (380.97 M) | ||||
| Working Capital | (4.03 M) | ||||
| Current Asset | 42.37 M | ||||
| Current Liabilities | 3.93 M | ||||
| Net Asset | 17.74 M |
About Mustang Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mustang Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mustang Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mustang Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Mustang Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mustang Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mustang Bio will appreciate offsetting losses from the drop in the long position's value.Moving against Mustang Stock
| 0.51 | WAT | Waters | PairCorr |
| 0.43 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.37 | BHC | Bausch Health Companies | PairCorr |
| 0.32 | VTRS | Viatris | PairCorr |
| 0.32 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Mustang Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mustang Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mustang Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mustang Bio to buy it.
The correlation of Mustang Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mustang Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mustang Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mustang Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Mustang Bio Piotroski F Score and Mustang Bio Altman Z Score analysis. To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.33) | Revenue Per Share (0) | Return On Assets (0.97) | Return On Equity (11.91) |
The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mustang Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.